EPZM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States...

Stats
今日成交量	0.00
平均成交量	4.18M
市值	0.00
EPS	$-0.210 ( 2022-08-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.704
ATR14	$0.0490 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-12	Giordano Michael F	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	13 060	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	3 380 951	Common Stock, par value $0.0001
2022-08-12	Conroy Kevin T	Sell	53 324	Common Stock, par value $0.0001

INSIDER POWER
-89.07
Last 98 transactions
Buy: 31 679 726 \| Sell: 42 571 145

音量相关性

長: 0.22 (neutral)

短: -0.56 (weak negative)

Signal:(61.298) Neutral

Epizyme Inc 相关性

10 最正相关
APOP	0.959
RMRM	0.951
MEIP	0.933
REAL	0.932
PCVX	0.93
NNOX	0.927
TYHT	0.925
CVGI	0.922
JFU	0.921
PRTA	0.921

10 最负相关
XMTR	-0.948
ASTR	-0.938
INFI	-0.922
HRZN	-0.922
UPLD	-0.921
DTEA	-0.92
OM	-0.92
VNET	-0.916
LUNG	-0.914
IRWD	-0.913

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Epizyme Inc 相关性 - 货币/商品

0.46
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.43
( neutral )

-0.46
( neutral )

Epizyme Inc 财务报表

Annual	2021
营收:	$37.43M
毛利润:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2021
营收:	$37.43M
毛利润:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2020
营收:	$15.76M
毛利润:	$10.70M (67.85 %)
EPS:	$-2.29

FY	2019
营收:	$23.80M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Epizyme Inc

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..